PET/CT in Evaluation of Early Response to Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer
A Kumar, R Kumar, V Seenu, S.D.Gupta, M Chawla, A Malhotra and S.N.Metha S | 2009-02-13
This study evaluates responses of PET/CT after two cycles of neo-adjuvant chemotherapy for breast cancer. It concludes 93% sensitivity, 75% specificity and 87% accuracy, suggesting PET/CT can differentiate responders from non-responders with high accuracy.
*FLUDEOXYGLUCOSE F 18 INJECTION
For Intravenous Use
INDICATIONS AND USAGE
Fludeoxyglucose F 18 injection (18F FDG) is indicated for positron emission tomography (PET) imaging in the following settings:
Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer.
Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging.
Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures.
IMPORTANT SAFETY INFORMATION
Radiation Risks: Radiation-emitting products, including fludeoxyglucose F 18 injection, may increase the risk for cancer, especially in pediatric patients. Use the smallest dose necessary for imaging and ensure safe handling to protect the patient and health care worker.
Blood Glucose Abnormalities: In the oncology and neurology setting, suboptimal imaging may occur in patients with inadequately regulated blood glucose levels. In these patients, consider medical therapy and laboratory testing to assure at least two days of normoglycemia prior to fludeoxyglucose F18 injection administration.
Adverse Reactions: Hypersensitivity reactions with pruritus, edema and rash have been reported; have emergency resuscitation equipment and personnel immediately available.
Siemens' PETNET Solutions is a manufacturer of Fludeoxyglucose F18 Injection (18F FDG). Indication and important safety information as approved by the US Food and Drug Administration can be found at the links below for 18F FDG, adult dose 5-10 mCi, administered by intravenous injection.